Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort

Figures & data

Table 1 Study designs of 6-month GnRH depot Phase III trials^2,6

Study	Drug	Patients	Stage	Injections
A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer	Leuprolide 45 mg	n = 111	Stage 1 to 4NxMx	Day 1, Week 24
Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, noncomparative, multicenter, Phase III study	Triptorelin 22.5 mg	n = 120	Stage T3 to 4NxMx, TxN1Mx, or TxNxM1	Day 1, Week 24

Table 2 Comparison of results leuprolide acetate with triptorelin pamoate^2,6

	Leuprolide	Triptorelin
Castration efficacy*
Day 29**	97.0%	97.5%
Month 12	99.0%	98.3%
Castration time	21.2 days	18.8 days
PSA decreases
Month 12	90.2%	96.0%
Adverse events
Hot flashes	57.6%	71.7%

Notes:

* Castration <50 ng/dL;

** Intent to treat population.

Abbreviation: PSA, prostate specific antigen.

Table 3 Comparison of 6-month vs shorter depots leuprolide acetate and triptorelin pamoate^2,6,37–40

	Day 29	Study completion
Leuprolide
1-month depot	94.0%	100.0%
3-month depot	98.0%	100.0%
6-month depot	99.0%	99%
Triptorelin
1-month depot	92.7%	99%
3-month depot	97.7%	97%
6-month depot	97.5%	98%

Table 4 Advantages of 6-month depots

Advantage	Results
Fewer frequent injections Fewer doctor vists	Reduced anxiety
	Decreased emotional burden
	Improved flexibility with scheduling
	Improved comfort
	Decreased site reactions
	Decreased cost
	Less missed visits
	Decreased breakthrough (theoretical)

CrawfordEDSartorOChuFPerezRKarlinGGarrettJSA 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol200617553353616406989

 PubMed Web of Science ®Google Scholar

LundströmEARenckenRKvan WykJHTriptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III studyClin Drug Investig200929757765

 PubMed Web of Science ®Google Scholar

MoroteJEsquenaSAbascalJMFailure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancerUrol Int20067713513816888418

 PubMed Web of Science ®Google Scholar

WechselHWZerbibMPaganoFCoptcoatMJRandomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancerEur Urol199630Suppl 17148977984

 PubMed Web of Science ®Google Scholar